Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07065773 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis
A Phase 2 study of Onychomycosis of Toenail, sponsored by Vanda Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 5
- Study locations
NCT07065773 is a Phase 2 study of Onychomycosis of Toenail that is active but no longer recruiting, run by Vanda Pharmaceuticals. The registered enrollment target is 50 participants. The trial reports 5 study locations across 5 states.
The verdict
NCT07065773, a Phase 2 study of Onychomycosis of Toenail, is active but no longer recruiting, sponsored by Vanda Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a multicenter, open label study designed to evaluate the safety, tolerability, and efficacy of topically administered VTR-297 solution. The efficacy objectives of the study will be assessed using fungal culture testing, Neutral Red Staining (NRS) microscopy examination, and KOH microscopy examination after 4 weeks of treatment with VTR-297.
Conditions Studied
Interventions
- DRUG Trichostatin A
Study Locations (5)
California
- Vanda Investigational Site - Fremont
Colorado
- Vanda Investigational Site - Denver
Minnesota
- Vanda Investigational Site - New Brighton
Texas
- Vanda Investigational Site - Pflugerville
Virginia
- Vanda Investigational Site - Forest
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-05-05 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07065773
The ClinicalTrials.gov registry entry for NCT07065773 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanda Pharmaceuticals, which has 68 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Onychomycosis of Toenail appearing as the primary indexed condition, and to 1 intervention - of which Trichostatin A is the first listed.
NCT07065773 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Colorado, Minnesota.
Frequently Asked Questions
What is clinical trial NCT07065773 about?
NCT07065773 is a clinical study titled "Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis". This is a multicenter, open label study designed to evaluate the safety, tolerability, and efficacy of topically administered VTR-297 solution. The efficacy objectives of the study will be assessed using fungal culture testing, Neutral Red Staining (NRS) microscopy examination, and KOH microscopy ex...
What is the current status of trial NCT07065773?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2025-05-05. Estimated completion is 2026-09.
What conditions does trial NCT07065773 study?
This clinical trial studies the following conditions: Onychomycosis of Toenail.
What interventions are being tested in trial NCT07065773?
The interventions under investigation include: Trichostatin A (DRUG).
Who is sponsoring clinical trial NCT07065773?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07065773 being conducted?
This trial has 5 study locations across California, Colorado, Minnesota, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Onychomycosis of Toenail
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.